Literature DB >> 12231036

Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

Peter R Carroll1, Philip W Kantoff, Steven P Balk, Myles A Brown, Anthony V D'amico, Daniel J George, Gary D Grossfeld, Candace S Johnson, William Kevin Kelly, Laurence Klotz, W Robert Lee, Deborah P Lubeck, David G Mcleod, William K Oh, Alan Pollack, Oliver Sartor, Matthew R Smith, Carol Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12231036     DOI： 10.1016/s0090-4295(02)01559-5

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  8 in total

1.  [Therapy induced regressive changes of prostate cancer].

Authors:  B Helpap; J Köllermann
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

2.  Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.

Authors:  Yaming Qiao; Lu Wang; Li-Qun Cai; Chen Tan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  J Urol       Date:  2011-01       Impact factor: 7.450

3.  Synergistic antimicrotubule therapy for prostate cancer.

Authors:  Vaishali Pannu; Prasanthi Karna; Hari Krishna Sajja; Deep Shukla; Ritu Aneja
Journal:  Biochem Pharmacol       Date:  2010-11-16       Impact factor: 5.858

4.  A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells.

Authors:  Ritu Aneja; Tohru Miyagi; Prasanthi Karna; Tucker Ezell; Deep Shukla; Meenakshi Vij Gupta; Clayton Yates; Sreenivasa R Chinni; Haiyen Zhau; Leland W K Chung; Harish C Joshi
Journal:  Eur J Cancer       Date:  2010-03-18       Impact factor: 9.162

5.  Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.

Authors:  Juan Wen; Yuan Zhao; Jinghe Li; Chunyan Weng; Jingjing Cai; Kan Yang; Hong Yuan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2013-02-19       Impact factor: 4.104

6.  Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

Authors:  Ilaria Pastina; Elisa Giovannetti; Aldo Chioni; Tristan M Sissung; Francesco Crea; Cinzia Orlandini; Douglas K Price; Claudia Cianci; William D Figg; Sergio Ricci; Romano Danesi
Journal:  BMC Cancer       Date:  2010-09-27       Impact factor: 4.430

Review 7.  [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].

Authors:  M Johannsen; K Wilke; D Schnorr; S A Loening
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

8.  Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

Authors:  Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif Alsharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 10.057
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.